A recent
report published by Infinium Global Research on the metabolic disorders
therapeutics market provides an in-depth analysis of segments and sub-segments in
the global as well as regional metabolic disorders therapeutics market. The
study also highlights the impact of drivers, restraints, and macro indicators
on the global and regional metabolic disorders therapeutics market over the
short term as well as long term. The report is a comprehensive presentation of
trends, forecasts, and dollar values of the global metabolic disorders
therapeutics market. According to the report, the global metabolic disorders
therapeutics market is projected to grow at a CAGR of 7% over the forecast
period of 2022-2028.
The value of the metabolic disorders
therapeutics market was over 70 billion in 2022 and is expected to reach USD
108 billion in 2028. Metabolism is a process in which the human body generates
energy from the food humans eat. The food that humans consume comprises
proteins, carbohydrates, and fats. Chemicals in the human digestive system
break the food parts down into sugars and acids. Metabolic disorders occur when
abnormal chemical reactions in the human body disturb this process. This is due
to enzyme deficiency: as all processes in the body are controlled by enzymes.
Any disturbance in the pathways involved in the development and metabolism of
carbohydrates, proteins, and fats, leads to metabolic disorder.
An increase
in academia-industry collaborations for drug developments is the key factor
responsible for the growth of the metabolic disorders therapeutics market.
Furthermore, the growing diabetic population is significantly contributing to
the growth of this market. As per International Agency for Research on Cancer,
there were 19.3 million new cancer cases worldwide in 2020, and the World
Health Organization estimates that there will be 422 million diabetic
individuals worldwide (WHO). Low compliance, the adherence rate for metabolic
disorder therapies, and the availability of alternative treatment options are
the major challenges faced by the players operating in this market. The global
metabolic disorders therapeutics market is anticipated to present several
opportunities for growth of market size over the forecast period due to
strategic collaborations and acquisitions and increased R & D investment.
North
America is expected to be the largest region in the market and Asia-Pacific is
expected to be the fastest growing region. The diabetic population in North
America is growing significantly, especially in countries such as the United
States. Apart from these, the number of people suffering from obesity is also
growing due to a sedentary lifestyle. People suffering from diabetes and
obesity are more prone to metabolic disorders. Therefore, demand for the
therapeutics for metabolic disorders is expected to remain high. Furthermore,
the high concentration of market players is also aiding the growth of the
market in North America. Companies such as Merck, Eli Lily, and others are
based in the North American region. Asia-Pacific is expected to be the fastest
growing region due to the high prevalence of diabetes and obesity in countries
such as India and China and also due to improving healthcare infrastructure in
the region.
The report
on the global metabolic disorders therapeutics market covers segments such as
disease type, and product. On the basis of disease type, the sub-markets include
diabetes, obesity, hypercholesterolemia, and lysosomal storage disease. On the
basis of product, the sub-markets include metachromatic leukodystrophy, globoid
leukodystrophy, hepatic encephalopathy, and others.
The report
provides profiles of the companies in the market such as AstraZeneca Plc, Novo
Nordisk, Sanofi, Merck, Eli Lily, Abbvie, Actelion Pharmaceuticals, Amicus
Therapeutics, Arena Pharmaceuticals, and Biocon.
The report
provides deep insights into the demand forecasts, market trends, and micro and
macro indicators. In addition, this report provides insights into the factors driving and restraining this market's growth. Moreover, The
IGR-Growth Matrix analysis given in the report brings an insight into the
investment areas that existing or new market players can consider. The report
provides insights into the market using analytical tools such as Porter's five
forces analysis and DRO analysis of the metabolic disorders therapeutics market.
Moreover, the study highlights current market trends and provides forecasts for
2022-2028. We also have highlighted future trends in the market that will
affect the demand during the forecast period. Moreover, the competitive
analysis given in each regional market brings an insight into the market share
of the leading players.
Please Choose One of them.